|
Infections associated with the addition of pertuzumab to trastuzumab-based chemotherapy. |
|
|
|
Consulting or Advisory Role - Puma Biotechnology |
Speakers' Bureau - Novartis (I) |
Research Funding - Cephalon; Novartis |
Other Relationship - Novo Nordisk |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |